Iterative refinement of a histologic algorithm for burn depth categorization based on 798 consecutive burn wound biopsies.

Autor: Phelan HA; LSUHSC, New Orleans, USA. Electronic address: hphel1@lsuhsc.edu., Holmes JH 4th; Wake Forest University, School of Medicine, USA., Hickerson WL; LSUHSC, New Orleans, USA., Cockerell CJ; Baylor University Medical Center at Dallas, USA., Shupp JW; MedStar Washington Hospital Center, USA., Carter JE; LSUHSC, New Orleans, USA.
Jazyk: angličtina
Zdroj: Burns : journal of the International Society for Burn Injuries [Burns] 2024 Feb; Vol. 50 (1), pp. 23-30. Date of Electronic Publication: 2023 Nov 07.
DOI: 10.1016/j.burns.2023.10.010
Abstrakt: Introduction: Our group previously reported a burn biopsy algorithm (BBA-V1) for categorizing burn wound depth. Here, we sought to promulgate a newer, simpler version of the BBA (BBA-V2).
Methods: Burn wounds undergoing excision underwent 4 mm biopsies procured every 25 cm 2 . Serial still photos were obtained at enrollment and at excision intraoperatively. Burn wounds assessed as likely to heal by 21 days were imaged within 72 h of injury and at 21 days. A sample of 798 burn wound biopsies were classified by both BBAV1 and BBAV2 algorithms. For nonoperative burn wounds, the proportion of healing versus nonhealing pixels at 21 days after injury were compared.
Results: The 798 biopsies were classified by BBAV1 as 24% SPT, 47% DPT, 28% FT and by BBAV2 as 3% SPT, 67% DPT, and 30% FT (p < 0.0001). Overall, the proportion of biopsies whose wound reclassification changed from a nonoperative to operative pathway was 21% (95% CI: 18-24%). Nonoperative wounds judged at injury as being SPT contained 12.8 million pixels. Repeat 21-day imaging revealed 11.3 million healed pixels (accuracy = 89.6% (95% CI: 89.59-89.62)).
Conclusions: BBA-V2 was associated with a significantly higher concordance with visual assessment for burn wounds clinically judged as deep partial and full thickness.
Competing Interests: Declaration of Competing Interest Dr. Phelan serves as a consultant with Avita Medical and SpectralMD. Dr. Holmes has equity positions in Abbott Labs, AbbVie, Change Healthcare Inc, & Imbed Biosciences, and is a consultant for Avita Medical & Stratatech/Mallinckrodt. Dr. Hickerson serves as a consultant for Avita Medical, Vericel, and Stedical. Dr. Cockerell has no disclosures. Dr. Shupp states that he has no competing disclosures relevant to imaging or burn depth determination. Dr. Carter is a stockholder for Permeaderm, Inc. and SpectralMD, and serves as Chief Medical Consultant for SpectralMD. He also serves as a consultant for Avita Medical and Polynovo Ltd. where, in lieu of compensation, all proceeds are donated to a local burn charity to support burn education, survivor programs, outreach, and research.
(Copyright © 2023. Published by Elsevier Ltd.)
Databáze: MEDLINE
Externí odkaz: